BACKGROUND: Cytomegalovirus (CMV) retinitis is a common opportunistic infection among patients with AIDS and still causes visual morbidity despite the wide spread usage of highly active antiretroviral therapy (HAART). The ubiquitous CMV pathogen contains a human interleukin-10 (IL-10) homolog in its genome and utilizes it to evade host immune reactions through an IL-10 receptor mediated immune-suppression pathway. METHODS: Effects of IL-10R1, IL-10 and previously described AIDS restriction gene variants are investigated on the development of CMV retinitis in the Longitudinal Study of the Ocular Complications of AIDS (LSOCA) cohort (N = 1284). RESULTS: In European Americans (n = 750), a haplotype carrying an amino acid changing variation in the cytoplasmic domain (S420L) of IL-10R1 can be protective (OR, 0.14; 95% CI, 0.02-0.94; P = .04) against, whereas another haplotype carrying an amino acid changing variation in the extracellular domain (I224V) of IL-10R1 can be more susceptible (OR, 6.21; 95% CI, 1.22- 31.54; P = .03) to CMV retinitis. In African Americans (n = 534), potential effects of IL-10 variants are observed. CONCLUSION: Host genetics may have a role in the occurrence of CMV retinitis in patients infected with HIV.
BACKGROUND:Cytomegalovirus (CMV) retinitis is a common opportunistic infection among patients with AIDS and still causes visual morbidity despite the wide spread usage of highly active antiretroviral therapy (HAART). The ubiquitous CMV pathogen contains a humaninterleukin-10 (IL-10) homolog in its genome and utilizes it to evade host immune reactions through an IL-10 receptor mediated immune-suppression pathway. METHODS: Effects of IL-10R1, IL-10 and previously described AIDS restriction gene variants are investigated on the development of CMV retinitis in the Longitudinal Study of the Ocular Complications of AIDS (LSOCA) cohort (N = 1284). RESULTS: In European Americans (n = 750), a haplotype carrying an amino acid changing variation in the cytoplasmic domain (S420L) of IL-10R1 can be protective (OR, 0.14; 95% CI, 0.02-0.94; P = .04) against, whereas another haplotype carrying an amino acid changing variation in the extracellular domain (I224V) of IL-10R1 can be more susceptible (OR, 6.21; 95% CI, 1.22- 31.54; P = .03) to CMV retinitis. In African Americans (n = 534), potential effects of IL-10 variants are observed. CONCLUSION: Host genetics may have a role in the occurrence of CMV retinitis in patients infected with HIV.
Authors: K V Komanduri; J Feinberg; R K Hutchins; R D Frame; D K Schmidt; M N Viswanathan; J P Lalezari; J M McCune Journal: J Infect Dis Date: 2001-03-12 Impact factor: 5.226
Authors: Dmitri V Zaykin; Peter H Westfall; S Stanley Young; Maha A Karnoub; Michael J Wagner; Margaret G Ehm Journal: Hum Hered Date: 2002 Impact factor: 0.444
Authors: Douglas A Jabs; Mark L Van Natta; John H Kempen; Peter Reed Pavan; Jennifer I Lim; Robert L Murphy; Larry D Hubbard Journal: Am J Ophthalmol Date: 2002-01 Impact factor: 5.258
Authors: Ulf Dittmer; Brent Race; Karin E Peterson; Ingunn M Stromnes; Ronald J Messer; Kim J Hasenkrug Journal: J Virol Date: 2002-01 Impact factor: 5.103
Authors: Juliet V Spencer; Kristen M Lockridge; Peter A Barry; Gaofeng Lin; Monica Tsang; Mark E T Penfold; Thomas J Schall Journal: J Virol Date: 2002-02 Impact factor: 5.103
Authors: Brandi C Jones; Naomi J Logsdon; Kristopher Josephson; Jennifer Cook; Peter A Barry; Mark R Walter Journal: Proc Natl Acad Sci U S A Date: 2002-07-01 Impact factor: 11.205
Authors: Angels Natividad; Martin J Holland; Kirk A Rockett; Julian Forton; Nkoyo Faal; Hassan M Joof; David C W Mabey; Robin L Bailey; Dominic P Kwiatkowski Journal: Hum Mol Genet Date: 2007-10-18 Impact factor: 6.150
Authors: Ping An; George W Nelson; Lihua Wang; Sharyne Donfield; James J Goedert; John Phair; David Vlahov; Susan Buchbinder; William L Farrar; William Modi; Stephen J O'Brien; Cheryl A Winkler Journal: Proc Natl Acad Sci U S A Date: 2002-07-11 Impact factor: 11.205
Authors: Ole Kirk; Peter Reiss; Caterina Uberti-Foppa; Markus Bickel; Jan Gerstoft; Christian Pradier; Ferdinand W Wit; Bruno Ledergerber; Jens D Lundgren; Hansjakob Furrer Journal: Ann Intern Med Date: 2002-08-20 Impact factor: 25.391
Authors: Aryan M Namboodiri; Paul J Nietert; Persis P Wadia; David B Miklos; Janardan P Pandey Journal: Viral Immunol Date: 2012-07-17 Impact factor: 2.257
Authors: Vivian P Young; Margarette C Mariano; Carolyn C Tu; Kathryn M Allaire; Selmir Avdic; Barry Slobedman; Juliet V Spencer Journal: J Infect Dis Date: 2017-03-15 Impact factor: 5.226
Authors: Efe Sezgin; Mark L van Natta; Alka Ahuja; Alice Lyon; Sunil Srivastava; Jennifer L Troyer; Stephen J O'Brien; Douglas A Jabs Journal: Am J Ophthalmol Date: 2011-03-10 Impact factor: 5.258
Authors: B Kasztelewicz; J Czech-Kowalska; B Lipka; B Milewska-Bobula; M K Borszewska-Kornacka; J Romańska; K Dzierżanowska-Fangrat Journal: Eur J Clin Microbiol Infect Dis Date: 2017-05-13 Impact factor: 3.267
Authors: Gary N Holland; Mark L Van Natta; David T Goldenberg; Rory Ritts; Ronald P Danis; Douglas A Jabs Journal: Invest Ophthalmol Vis Sci Date: 2019-05-01 Impact factor: 4.799